Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christian Georg Stief has a total of 952 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Preoperative Sarcopenia on Survival and Perioperative Outcomes After Radical Cystectomy for Bladder Cancer

    by Benso John, Jozefina Casuscelli, Alexander Buchner, Isabel Brinkmann, Frederik Kolligs, Marie Semmler, Yannic Volz, Mahmudur R. Khan, Christian G. Stief, Gerald Schulz, et al.

  • Open Access

    Does Timing Matter? Perioperative Outcomes and Quality of Life After Early Versus Delayed Radical Cystectomy Following BCG Therapy

    by Yannic Volz, Verena Ghali, Nikolaos Pyrgidis, Matthias P. Fabritius, Benedikt Ebner, Marie Semmler, Marc Kidess, Raphael Scheuringer, Julian Marcon, Patrick Keller, et al.

    Objectives: To determine whether the timing of radical cystectomy (RC), either early versus delayed following BCG therapy, affects perioperative outcomes and health-related quality of life (HRQOL) in patients with very-high-risk non–muscle invasive bladder cancer (NMIBC). While existing data focus on oncological endpoints, the impact of BCG on these outcomes remains unevaluated. Methods: We retrospectively analysed a prospectively maintained database of 126 patients undergoing RC for very-high-risk NMIBC at a tertiary referral centre, stratified into early RC (n = 81) and delayed RC (n = 45, following BCG therapy). Perioperative outcomes, HRQOL assessed by EORTC-QLQ-C30 at baseline and 3, 12, and 24 months postoperative, and overall survival (OS) were compared. Longitudinal HRQOL changes were analysed using linear mixed-effects models adjusted for age and Carcinoma in situ (CIS) status, correcting for multiple comparisons. Results: Groups were well-balanced at baseline regarding age, sex, BMI, and ECOG performance status. No significant between-group differences were observed in overall complication rates, hospital stay length, or any QLQ-C30 domain at any timepoint, including global health status (GHS), in linear mixed-effects models accounting for repeated measures and multiple comparisons. OS did not differ between groups (p = 0.720). Conclusions: Prior BCG therapy does not adversely influence perioperative outcomes or HRQOL following RC for very-high-risk NMIBC. These findings support the initial use of BCG in eligible patients, as a trial of intravesical therapy does not appear to compromise surgical safety or postoperative quality of life when cystectomy is ultimately required.

  • Open Access

    Sizing up Testicular Masses: Clinical Implications of Lesion Size and Contralateral Biopsy

    by Elena Katharina Berg, Gwendolin Seidel, Lennert Eismann, Yannic Volz, Paulo Leonardo Pfitzinger, Philipp Weinhold, Gerald Bastian Schulz, Patrick Keller, Isabel Katharina Brinkmann, Fabian Horné, et al.

    Background/Objectives: Accurate preoperative discrimination between benign and malignant testicular masses remains challenging. Lesion size has been suggested as a predictor, but robust cutoffs and the role of contralateral biopsy remain uncertain. Methods: We retrospectively analyzed a prospectively maintained single-center database of 387 patients treated for testicular lesions between December 2013 and November 2024. Patients with malignant non-germ cell histologies or prior systemic GCT therapy were excluded. Lesion size was evaluated as a predictor of malignancy using ROC analysis, logistic regression, and predefined cutoffs (5, 8, 10, 15 mm). Associations between contralateral biopsy results and clinical variables were assessed using uni- and multivariable analyses. Results: Of 387 patients, 284 (73.4%) had malignant GCTs. Malignant lesions were significantly larger than benign ones (median 25.0 vs. 5.5 mm, p < 0.001). Lesion size showed good discrimination between benign and malignant lesions (AUC 0.829, 95% CI 0.784–0.874), with a Youden-derived optimal cutoff of 12.5 mm. Internal bootstrap validation (2000 resamples) yielded a median optimal cutoff of 12.5 mm (95% percentile interval 7.45–19.5 mm), indicating uncertainty regarding the exact threshold. Among 360 patients with complete clinical and tumor-marker data, combining lesion size with age, AFP, β-HCG, and LDH significantly improved discrimination compared with lesion size alone (AUC 0.863 vs. 0.818; DeLong p = 0.003). Contralateral biopsy was performed in 249 patients, with 7 (2.8%) positive for GCNIS. Younger age was associated with contralateral GCNIS, while tumor size, serum markers, and histology were not predictive. Multivariable analysis showed no significant predictors. Conclusions: Lesion size is a strong predictor of malignant histology, although the optimal size threshold remains subject to uncertainty. Combining lesion size with readily available clinical and biochemical parameters may further improve preoperative risk stratification. Contralateral GCNIS was rare and not reliably predicted, supporting individualized biopsy strategies.

  • Open Access

    Plasma infrared molecular fingerprinting for prostate cancer detection: prospective evidence for a partially PSA-independent signal

    by Philip Jacob, Michael Chaloupka, Tarek Eissa, Joseph Rebel, Jacqueline Aschauer, Carola Pfundmeier, Sabine Witzens, Isabel Brinkmann, Lennert Eismann, Nikolaos Pyrgidis, et al.

  • Open Access

    Baseline Sarcopenia is Associated With Overall Survival but Not Toxicity in Patients Receiving Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

    by Can Aydogdu, Simon Hahn, Benso John, Isabel Brinkmann, Judith Fischer, Benazir Enzinger, Marie Semmler, Elena K. Berg, Frederik Kolligs, Christian G. Stief, et al.

  • Open Access

    Plasma infrared molecular fingerprinting for prostate cancer detection: prospective evidence for a partially PSA-independent signal

    by Mihaela Zigman, Philip Jacob, Michael Chaloupka, Tarek Eissa, Joseph Rebel, Jacqueline Aschauer, Carola Pfundmeier, Sabine Witzens, Isabel Brinkmann, Lennert Eismann, et al.

    Background: Prostate-specific antigen (PSA) testing has limited specificity, particularly at intermediate PSA concentrations, contributing to diagnostic uncertainty in prostate cancer (PCa). Infrared molecular fingerprinting (IMF) provides rapid plasma-based readout of disease-associated biochemical alterations, and may capture molecular information that is not fully reflected by PSA concentration.Methods: In the prospective Lasers4Life study, plasma from 2,024 men was analysed, including 1,012 treatment-naïve PCa patients, 752 men with benign prostatic hyperplasia (BPH), and 260 asymptomatic controls. Classification models were evaluated using cross-validation and, for PCa-vs-BPH discrimination, temporally independent held-out cohort testing. Diagnostic performance was quantified by the area under the receiver operating characteristic curve (ROC AUC) and examined across PSA strata, comorbidities and medications.Results: IMF discriminated PCa from asymptomatic controls (AUC 0.79 ± 0.08) and from BPH (AUC 0.67 ± 0.04) in cross-validation. In an exploratory age- and PSA-matched subset of individuals with PSA below 12 ng/mL (comprising 200 PCa and 200 BPH cases), IMF showed higher discrimination than PSA alone (AUC 0.63 vs 0.56; p < 1×10⁻⁴). Most examined comorbidities and medications did not strongly alter IMF performance, except prostatitis modestly reduced discrimination.Conclusions: IMF detected PCa-associated molecular signatures in plasma, including signals partly independent of PSA. However, diagnostic discrimination was modest, and clinical utility remains to be proven. Independent validation, clinically significant PCa endpoints, and demonstration of additive value within established diagnostic pathways are required.

  • Open Access

    Trends in Treatment and Perioperative Outcomes of Upper Tract Urothelial Carcinoma: The Evolving Role of Lymphadenectomy and Neoadjuvant Chemotherapy

    by Robert Bischoff, Nikolaos Pyrgidis, Benedikt Ebner, Yannic Volz, Julian Hermans, Marie Semmler, Patrick Keller, Gerald B. Schulz, Julian Marcon, Philipp Weinhold, et al.

    Objectives: Real-world data on surgical and multimodal management of upper tract urothelial carcinoma (UTUC) are limited. This study examined epidemiological trends, nephron-sparing surgery adoption, and the perioperative impact of lymphadenectomy (LND) and neoadjuvant chemotherapy (NAC). Methods: The German Nationwide Inpatient Data (GRAND) registry (2005–2023) identified UTUC patients undergoing radical nephroureterectomy (RNU), endoscopic laser destruction, or segmental ureteral resection (SUR) using OPS codes. Demographics, comorbidities, complications, and in-hospital mortality were extracted from ICD-10-GM data. Multivariable regression adjusted for baseline comorbidities assessed associations between treatment type, LND, NAC, and perioperative outcomes. Results: Among 53,427 UTUC patients, 77.3% underwent RNU, 13.8% endoscopic laser destruction, and 8.9% SUR. Endoscopic laser use rose from <10% (2005) to about 20% (2023). LND was performed in 13% of RNU cases, increasing from 1.1% to 19%. LND was associated with higher risks of transfusion (OR 1.47, 95% CI 1.37–1.57), acute kidney injury (OR 1.19, 95% CI 1.07–1.32), and ICU admission (OR 1.21, 95% CI 1.13–1.30), without affecting in-hospital mortality. NAC was given to 1.7% of patients, with a five-fold increase over time, and was associated with more transfusions (OR 1.28, 95% CI 1.07–1.52) and urinomas (OR 2.31, 95% CI 1.31–3.78), but not mortality. Conclusions: UTUC management is evolving, with growing use of endoscopic laser therapy and guideline-aligned lymphadenectomy during nephroureterectomy. Neoadjuvant chemotherapy remains underused despite acceptable perioperative safety, highlighting the need for increased awareness to optimize multimodal treatment.

  • Extended versus Standard Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Cohort Study

    by Can Aydogdu, Florian Urban, Elena Berg, Melanie Götz, Severin Rodler, Isabel Brinkmann, Benazir Enzinger, Marie Semmler, Frederik Kolligs, Marina Hoffmann, et al.

    Introduction: Androgen deprivation therapy (ADT) plus 6 cycles of docetaxel was the global first-line standard for metastatic hormone-sensitive prostate cancer (mHSPC) before triplet regimens emerged. In many regions, this approach remains the only accessible option. Whether extending docetaxel beyond six cycles provides additional benefit remains uncertain. This study evaluated the efficacy and safety of extended docetaxel in newly diagnosed mHSPC. Methods: We conducted a retrospective cohort study of 98 mHSPC patients treated with ADT plus docetaxel (75 mg/m2) at a German tertiary center (2014–2022). Patients were grouped by treatment duration: 4–6 cycles (n = 60) vs. 7–10 cycles (n = 38). Progression-free survival (PFS1), time to progression after subsequent therapy, and overall survival (OS) were analyzed using Kaplan-Meier and Cox models. Adverse events were graded per CTCAE v5.0. Results: Median PFS1 was similar between groups (12.6 vs. 12.2 months; HR 1.13; p = 0.713), as was OS (38.5 vs. 52.9 months; HR 0.99; p = 0.958). Extended treatment led to higher overall toxicity (68.4% vs. 38.3%; p = 0.004), mainly peripheral neuropathy and dermatologic events, while severe events (grade ≥3) were comparable (7.9% vs. 8.3%). Conclusion: Extending docetaxel beyond six cycles in first-line mHSPC offers no survival advantage and increases toxicity. Six cycles remain an effective, pragmatic standard where triplet therapy is unavailable.

  • Open Access

    Blasenkarzinom und ableitende Harnwege

    by Christian Stief, Viktor Grünwald, Christian Weiss

  • Open Access

    Pine-Extracted Phytosterol β-Sitosterol (APOPROSTAT® Forte) Inhibits Both Human Prostate Smooth Muscle Contraction and Prostate Stromal Cell Growth, Without Cytotoxic Effects: A Mechanistic Link to Clinical Efficacy in LUTS/BPH

    by Alexander Tamalunas, Felix Schierholz, Henrik Poth, Victor Vigodski, Michael Brandstetter, Anna Ciotkowska, Beata Rutz, Sheng Hu, Leo Federico Stadelmeier, Heiko Schulz, et al.

    Introduction: Medical treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) targets prostate smooth muscle tone for rapid relieve of symptoms and prostate size to prevent disease progression. Recently, EAU guidelines introduced phytomedicines for treatment of LUTS/BPH. Phytosterols may reduce the risk of prostate diseases and seem to be the smallest common denominator between different phytotherapeutic preparations. Thus, we investigated the effects of the highly concentrated phytosterol β-sitosterol on human prostate smooth muscle contraction and cellular functions, including contraction and growth of prostate stromal cells. Materials and Methods: APOPROSTAT® forte capsules (>70% β-sitosterol, ethanol extract of Pinus pinaster) were dissolved in ethanol. Contractions were induced in human prostate tissues (n = 100) obtained from radical prostatectomy and assessed in organ bath setups. Cytoskeletal organization, proliferation, viability, cytotoxicity, and contraction in stromal cells (WPMY-1) were assessed using phalloidin staining, EdU, colony formation, CCK-8, flow cytometry, and matrix collagen assays. Results: APOPROSTAT® forte (0.1–30 µg/mL) inhibited adrenergic, non-adrenergic, and neurogenic contractions of human prostate tissues by up to 71%, 69%, and 63%, respectively, in a dose-dependent manner. In WPMY-1 cells, it reduced proliferation and actin organization by up to 67% and 75% after 72 h, without affecting viability or inducing cytotoxicity. Colony formation decreased by up to 60% after 168 h, and contraction in collagen matrix assays was reduced by 57% in a concentration- and time-dependent manner. Conclusions: The natural phytosterol β-sitosterol effectively inhibits both prostate contraction and growth with a favorable safety profile, supporting its beneficial role in LUTS management through phytotherapy.